Ruxolitinib impairs phenotype and function of DCs. (A) Human monocytes cultured under DC-driving conditions with final LPS stimulation were exposed every other day to different concentrations of ruxolitinib (0.2 µM, 0.5 µM, and 1 µM on day 0, 2, 4, 6; ▪) or DMSO (□) throughout the differentiation period and analyzed for expression of DC and activation markers. Results are from 1 experiment representative of at least 3. (B) Expression of DC and activation markers after exposure of moDCs to ruxolitinib (1 µM, 5 µM, and 10 µM) on day 5, followed by subsequent final maturation with LPS on day 6, are shown. Filled black graphs represent negative controls. (C) Monocytes were cultured under DC-driving conditions and treated with ruxolitinib once on day 5, followed by LPS activation on day 6. Supernatants were collected on day 7 and analyzed for IL-12 production using a commercially available enzyme-linked immunosorbent assay. Results of 1 representative donor are shown. The significance was calculated according to the 1-way ANOVA Dunnett multiple comparison test and is related to the vehicle control. *P < .1; **P < .01; ***P < .001.